Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + fresh frozen plasma
- Development stage
- Unknown
- Lead developer
- Edith Wolfson Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This investigational combination therapy consists of the anti-CD20 monoclonal antibody rituximab (marketed as Rituxan or Mabthera) and fresh frozen plasma (FFP). Developed by Wolfson Medical Center, the regimen is specifically intended for the treatment of advanced refractory chronic lymphocytic leukemia (CLL). The therapeutic rationale is based on the observation that many CLL patients possess deficiencies in the complement system, which significantly limits the efficacy of rituximab by impairing complement-dependent cytotoxicity (CDC). By administering FFP as an exogenous source of complement proteins immediately prior to rituximab infusion, the protocol aims to restore and enhance the immune-mediated destruction of malignant B cells. Clinical evaluation in Phase II trials has focused on patients who are refractory to standard fludarabine-based treatments.
- Brand names
- RituxanMabthera
- Other names
- Rituximab plus FFPMabthera plus FFPFFP and Rituximab
02
Targets
Beyond the preview
Go deeper on rituximab + fresh frozen plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + fresh frozen plasma.